

# William E Brady

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11248248/publications.pdf>

Version: 2024-02-01

22  
papers

1,727  
citations

393982

19  
h-index

676716

22  
g-index

22  
all docs

22  
docs citations

22  
times ranked

2123  
citing authors

#	ARTICLE	IF	CITATIONS
1	Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2013, 14, 134-140.	5.1	322
2	A Community-Based, Randomized Trial of Ezetimibe Added to Statin Therapy to Attain NCEP ATP III Goals for LDL Cholesterol in Hypercholesterolemic Patients: The Ezetimibe Add-On to Statin for Effectiveness (EASE) Trial. <i>Mayo Clinic Proceedings</i> , 2005, 80, 587-595.	1.4	241
3	Human Serum Carotenoid Concentrations Are Related to Physiologic and Lifestyle Factors. <i>Journal of Nutrition</i> , 1996, 126, 129-137.	1.3	210
4	Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. <i>American Journal of Cardiology</i> , 2004, 93, 1487-1494.	0.7	184
5	Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. <i>Current Medical Research and Opinion</i> , 2006, 22, 2041-2053.	0.9	101
6	Is adjuvant chemotherapy indicated in ovarian immature teratomas? A combined data analysis from the International Collaborative. <i>Cancer</i> , 2016, 122, 230-237.	2.0	91
7	Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG) Tj ETQq1 1 0.784314 rgBT /Overbo 541-553.	6.3	75
8	Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome. <i>Diabetes and Vascular Disease Research</i> , 2006, 3, 93-102.	0.9	65
9	An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience. <i>Gynecologic Oncology</i> , 2017, 147, 243-249.	0.6	61
10	Influence of Using Different Sources of Carotenoid Data in Epidemiologic Studies. <i>Journal of the American Dietetic Association</i> , 1996, 96, 1271-1275.	1.3	51
11	Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001). <i>Gynecologic Oncology</i> , 2018, 150, 9-13.	0.6	44
12	Lipid altering-efficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin: a meta-analysis of pooled data from 14 clinical trials. <i>Current Medical Research and Opinion</i> , 2005, 21, 1123-1130.	0.9	42
13	A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2016, 140, 204-209.	0.6	40
14	A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2017, 147, 283-290.	0.6	37
15	Phase II study of aximogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2020, 158, 562-569.	0.6	35
16	A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2014, 133, 537-541.	0.6	31
17	Effectiveness of Ezetimibe Added to Ongoing Statin Therapy in Modifying Lipid Profiles and Low-Density Lipoprotein Cholesterol Goal Attainment in Patients of Different Races and Ethnicities: A Substudy of the Ezetimibe Add-On to Statin for Effectiveness Trial. <i>Mayo Clinic Proceedings</i> , 2006, 81, 1177-1185.	1.4	28
18	Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy. <i>Clinical Cancer Research</i> , 2017, 23, 1955-1966.	3.2	27

#	ARTICLE	IF	CITATIONS
19	Is carboplatin-based chemotherapy as effective as cisplatin-based chemotherapy in the treatment of advanced-stage dysgerminoma in children, adolescents and young adults?. <i>Gynecologic Oncology</i> , 2018, 150, 253-260.	0.6	21
20	A Phase I Evaluation of Extended Field Radiation Therapy With Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women With Cervical Carcinoma Metastatic to the Para-aortic Lymph Nodes: An NRG Oncology/Gynecologic Oncology Group Study. <i>Gynecologic Oncology</i> , 2018, 151, 202-207.	0.6	10
21	Clinical trial methodology in rare gynecologic tumor research: Strategies for success. <i>Gynecologic Oncology</i> , 2018, 149, 605-611.	0.6	8
22	LDL-C goal attainment with ezetimibe plus simvastatin coadministration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD. <i>MedGenMed: Medscape General Medicine</i> , 2005, 7, 3.	0.2	3